Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

JCO Early Release, published online ahead of print Mar 12 2012
Journal of Clinical Oncology, 10.1200/JCO.2011.39.6671

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hollevoet, K.
Right arrow Articles by van Meerbeeck, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollevoet, K.
Right arrow Articles by van Meerbeeck, J. P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Delicious   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J. Zhang, S. Khanna, Q. Jiang, C. Alewine, M. Miettinen, I. Pastan, and R. Hassan
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
Clin. Cancer Res., March 15, 2017; 23(6): 1564 - 1574.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir RevHome page
A. C. Bibby, S. Tsim, N. Kanellakis, H. Ball, D. C. Talbot, K. G. Blyth, N. A. Maskell, and I. Psallidas
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Eur. Respir. Rev., November 30, 2016; 25(142): 472 - 486.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Napolitano, D. J. Antoine, L. Pellegrini, F. Baumann, I. Pagano, S. Pastorino, C. M. Goparaju, K. Prokrym, C. Canino, H. I. Pass, et al.
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Clin. Cancer Res., June 15, 2016; 22(12): 3087 - 3096.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J. Creaney and B. W. S. Robinson
Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies
Thorax, April 1, 2015; 70(4): 374 - 375.
[Full Text] [PDF]


Home page
Eur J Cardiothorac SurgHome page
I. Opitz, R. Bueno, E. Lim, H. Pass, U. Pastorino, M. Boeri, G. Rocco, and on behalf of the ESTS Biology Club
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know
Eur J Cardiothorac Surg, October 1, 2014; 46(4): 602 - 606.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Lamote, K. Nackaerts, and J. P. van Meerbeeck
Strengths, Weaknesses, and Opportunities of Diagnostic Breathomics in Pleural Mesothelioma--A Hypothesis
Cancer Epidemiol. Biomarkers Prev., June 1, 2014; 23(6): 898 - 908.
[Abstract] [Full Text] [PDF]


Home page
BMJ OpenHome page
A. Cui, X.-G. Jin, K. Zhai, Z.-H. Tong, and H.-Z. Shi
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
BMJ Open, February 23, 2014; 4(2): e004145 - e004145.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
M. CORRADI, M. GOLDONI, R. ALINOVI, M. TISEO, L. AMPOLLINI, S. BONINI, P. CARBOGNANI, A. CASALINI, and A. MUTTI
YKL-40 and Mesothelin in the Blood of Patients with Malignant Mesothelioma, Lung Cancer and Asbestosis
Anticancer Res, December 1, 2013; 33(12): 5517 - 5524.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
D. W. Henderson, G. Reid, S. C. Kao, N. van Zandwijk, and S. Klebe
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
J. Clin. Pathol., October 1, 2013; 66(10): 847 - 853.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
I. Pantazopoulos, P. Boura, T. Xanthos, and K. Syrigos
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
Eur. Respir. J., March 1, 2013; 41(3): 706 - 715.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
R. Kratzke
Detection of Mesothioloma Remains a Conundrum
J Natl Cancer Inst, February 20, 2013; 105(4): 254 - 255.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2012 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online